Listen
ZYCLARA (imiquimod), topical chemotherapy
DERMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Apr 15 2016
Reason for request
Inclusion
No clinical benefit demonstrated in the topical treatment of actinic keratosis
- ZYCLARA, imiquimod 3.75%, has Marketing Authorisation in the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
- It has demonstrated its efficacy versus placebo but has not been compared with ALDARA, imiquimod 5%.
- This is a second-line treatment, after failure of other topical treatments.
Clinical Benefit
| Low |
- |
Clinical Added Value
| no clinical added value |
- |
English version
Contact Us
Évaluation des médicaments
